Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC) Meeting Abstract
| Authors: | Dickler, M.; Rugo, H.; Caravelli, J.; Brogi, E.; Sachs, D.; Panageas, K.; Flores, S.; Moasser, M.; Norton, L.; Hudis, C. |
| Abstract Title: | Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC) |
| Meeting Title: | 40th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 22 |
| Issue: | 14 Suppl. |
| Meeting Dates: | 2004 Jun 5-8 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2004-07-15 |
| Start Page: | 127S |
| Language: | English |
| ACCESSION: | WOS:000223512400503 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2004.22.90140.2001 |
| Notes: | Meeting Abstract: 2001 -- 40th Annual Meeting of the American-Society-of-Clinical-Oncology -- JUN 05-08, 2004 -- New Orleans, LA -- S -- Source: Wos |
